Skip to main navigation Skip to search Skip to main content

Recent developments in the treatment of advanced bladder cancer

  • Thomas Jefferson University

Research output: Contribution to journal › Review article › peer-review

38 Scopus citations

Abstract

Urothelial carcinoma of the bladder is a common malignancy which has historically been difficult to treat in its advanced stages. Clinically effective treatment options for locally advanced/inoperable or metastatic urothelial carcinoma (mUC) consisted of cisplatin-based chemotherapy regimens, with few other impactful therapeutic options. The past 2 years have seen a remarkable shift in the therapeutic landscape of mUC, with 5 novel immunotherapy agents receiving FDA approval for mUC, including first-line and second-line postplatinum settings. There are now many important clinical trials ongoing seeking to answer how best to use chemotherapy, immunotherapy, and targeted therapy agents in patients with mUC. Here we review the current standard of care for patients with mUC based on published data from the past 2 years, and look forward toward future research directions.

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume36
Issue number3
DOIs
StatePublished - Mar 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bladder cancer
  • Checkpoint inhibitors
  • Chemotherapy
  • Clinical trials
  • Immunotherapy
  • Platinum ineligible
  • Targeted therapy
  • Urothelial carcinoma

Fingerprint

Dive into the research topics of 'Recent developments in the treatment of advanced bladder cancer'. Together they form a unique fingerprint.

Cite this